Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in England

References

• Smith A, Crouch S, Lax S, et al. Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's haematological malignancy research network. Br J Cancer. 2015;112(9):730–1584.
   Web of Science ®Google Scholar
• McKay P, Leach M, Jackson B, et al. Guideline for the management of mantle cell lymphoma. Br J Haematol. 2018;182(1):46–62.
   PubMed Web of Science ®Google Scholar
• NICE. Non-Hodgkin’s lymphoma: diagnosis and management [NG52]. 2016.
   Google Scholar
• Rule S. The modern approach to mantle cell lymphoma. Hematol Oncol. 2019;37(S1):66–69.
   PubMedGoogle Scholar
• Eyre TA, Follows G, Hodson A, et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. haematologica. 2019;104(2):e71–e71.
   Web of Science ®Google Scholar
• Cohen BJ, Moskowitz C, Straus D, et al. Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leuk Lymphoma. 2001;42(5):1015–1022.
   PubMed Web of Science ®Google Scholar
• Wang M, Schuster SJ, Phillips T, et al. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). J Hematol Oncol. 2017;10(1):171.
   PubMedGoogle Scholar
• Arcaini L, Lamy T, Walewski J, et al. Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma. Br J Haematol. 2018;180(2):224–235.
   PubMed Web of Science ®Google Scholar
• Smith A, Roman E, Appleton S, et al. Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK's Haematological Malignancy Research Network (HMRN). Br J Haematol. 2018;181(2):215–228.
   PubMed Web of Science ®Google Scholar
• Kumar A, Sha F, Toure A, et al. Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. Blood Cancer J. 2019;9(6):50.
   PubMed Web of Science ®Google Scholar
• Reyes Arranz Jose Luis B, Miguel Ángel C, et al. editors. Management of relapsed/refractory mantle cell lymphoma (MCL) in routine clinical practice in Spain (IMORS study). Descriptive Data and Efficacy Results; 2018. Available from: https://library.ehaweb.org/eha/2018/stockholm/216049/reyes.arranz.management.of.relapsed.refractory.mantle.cell.lymphoma.28mcl29.in.html?f=menu=6*ce_id=1346*ot_id=19046*media=3*marker=168
   Google Scholar
• McCulloch R, Lewis D, Crosbie N, et al. Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients. Br J Haematol. 2021;193(2):290–298.
   PubMed Web of Science ®Google Scholar
• McCulloch R, Rule S, Eyre TA, et al. Ibrutinib at first relapse for mantle cell lymphoma: a United Kingdom real world analysis of outcomes in 169 patients. Blood. 2019;134(Supplement_1):3993–3993.
   Google Scholar
• Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331–1342.
   PubMed Web of Science ®Google Scholar
• Wang ML, Munoz J, Goy A, et al. editors. KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study. ASH; 2019. Blood.
   Google Scholar
• Wang Y, Lin R, Xu L-P, et al. One-Year follow-up of ZUMA-2, the multicenter, registrational study of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma. Blood. 2020;136(Supplement 1):20–22.
   Google Scholar
• NICE. Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma. 2021.
   Google Scholar
• NICE Decision Support Unit. NICE DSU Technical Support Document 19 Partitioned Survival Analysis for Decision Modelling in Health Care: A Critical Review; 2017.
   Google Scholar
• Hess G, Dreyling M, Oberic L, et al. editors. KTE-X19 versus standard of care for relapsed/refractory mantle cell lymphoma previously treated with Bruton tyrosine kinase inhibitors: Real-World evidence from Europe. EHA; 2021.
   Google Scholar
• Dreyling M, Shah B, Wu JJ., et al. Efficacy Outcomes Following Treatment with BTKi for Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL): A Literature-Based Meta-Analysis. Abstract accepted, ISPOR library; 2022-05;SA29 [Internet]. Available from: https://www.ispor.org/heor-resources/presentations-database/presentation/intl2022-3461/116051
   Google Scholar
• Gauthier J, Maloney DG. Allogeneic transplantation and chimeric antigen receptor-engineered T-cell therapy for relapsed or refractory mantle cell lymphoma. Hematol Oncol Clin North Am. 2020;34(5):957–970.
   PubMed Web of Science ®Google Scholar
• NICE. Guide to the methods of technology appraisal 2013. Available from: https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781.
   Google Scholar
• Simons CL, Malone D, Wang M, et al. Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States. J Med Econ. 2021;24(1):421–431.
   PubMed Web of Science ®Google Scholar
• Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974;19(6):716–723.
   Web of Science ®Google Scholar
• NICE. Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma after 2 or more systemic therapies [ID1115]. 2018.
   Google Scholar
• Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491–502.
   PubMed Web of Science ®Google Scholar
• NICE. Tisagenlecleucel-T for treating relapsed or refractory diffuse large B-cell lymphoma [ID1166]: Committee Papers. 2018.
   Google Scholar
• Roth JA, Sullivan SD, Lin VW, et al. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States. J Med Econ. 2018;21(12):1238–1245.
   PubMed Web of Science ®Google Scholar
• ICER. CAR-T therapies: final evidence report. [Internet]; ICER. 2018 [cited 2021 Dec 9]. Available from: https://icer-review.org/material/car-t-final-report/.
   Google Scholar
• Lambert PC, Dickman PW, Weston CL, et al. Estimating the cure fraction in population-based cancer studies by using finite mixture models. J Royal Stat Soc C. 2010;59(1):35–55.
   Google Scholar
• Rutherford MJ, Lambert PC, Sweeting MJ, et al. NICE DSU technical support document 21. Flexible Methods for Survival Analysis. [Internet]; 2020 [cited 2021 Dec 14]. Available from: http://nicedsu.org.uk/.
   Google Scholar
• Maurer MJ, Ghesquières H, Jais J-P, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014;32(10):1066–1073.
   PubMed Web of Science ®Google Scholar
• British National Formulary. [Internet]; [cited 2021 Oct 8]. Available from: https://bnf.nice.org.uk.
   Google Scholar
• NHS. NHS National Reference Cost schedule 2018-19 2019. Available from: https://www.england.nhs.uk/national-cost-collection/#ncc1819.
   Google Scholar
• Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27(23):3822–3829.
   PubMed Web of Science ®Google Scholar
• NICE. Ibrutinib for treating relapsed or refractory mantle cell lymphoma. Technology appraisal guidance [TA502] – Committee Papers. 2016.
   Google Scholar
• Bennett MI, Ziegler L, Allsop M, et al. What determines duration of palliative care before death for patients with advanced disease? A retrospective cohort study of community and hospital palliative care provision in a large UK city. BMJ Open. 2016;6(12):e012576.
   PubMed Web of Science ®Google Scholar
• Curtis LA, Burns A. Unit Costs of Health and Social Care 2020; 2021. Available from: https://www.pssru.ac.uk/project-pages/unit-costs/unit-costs-2020/.
   Google Scholar
• Ara R, Brazier JE. Populating an economic model with health state utility values: moving toward better practice. Value Health. 2010;13(5):509–518.
   PubMed Web of Science ®Google Scholar
• Hettle R, Corbett M, Hinde S, et al. Review of cost-effectiveness evidence for chimeric antigen receptor T-cell therapy and other interventions for acute lymphocytic leukaemia. [Internet]. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal. NIHR Journals Library. 2017 [cited 2021 Aug 11]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK424721/.
   Google Scholar
• Sarkar RR, Gloude NJ, Schiff D, et al. Cost-Effectiveness of chimeric antigen receptor T-Cell therapy in pediatric relapsed/refractory B-Cell acute lymphoblastic leukemia. J Natl Cancer Inst. 2019;111(7):719–726.
   PubMedGoogle Scholar
• Liu R, Snider JT, Diakite I Cost effectiveness of axicabtagene ciloleucel (axi-cel) and tisagenlecleucal (tisa-cel) for adult patients with relapsed or refractory large B-cell lymphoma (RR LBCL) in the US. EHA library; 06/12/20; 294211; EP1731. 2020, et al. 2020.
   Google Scholar
• Heine R, Thielen FW, Koopmanschap M, et al. Health economic aspects of chimeric antigen receptor T-cell therapies for hematological cancers: present and future. Hemasphere. 2021;5(2):e524.
   PubMed Web of Science ®Google Scholar